Evergreen Bioworks, Inc.
AI Directed Evolution of Peptide Therapeutics
Evergreen is using AI with directed evolution in multi-cellular animal models to rapidly engineer peptide IP for maximizing human health
Mission
Our mission is to build the best-in-class peptide engineering platform for biologic therapeutics targeting neurodegenerative diseases and aging
We strive to achieve our mission by developing a proprietary R&D platform whose synergistic pairing of AI with a first-in-class animal model for directed evolution could enable faster engineering of peptide therapeutics with increased probability of successful clinical translation
Why Now?
Moral Imperative: Maximizing human health in a world of aging demographics requires therapies targeting diseases of old age
Unmet Need: Among diseases of old age, neurodegenerative diseases are particularly underserved by effective therapies
AI Revolution: The evolving field of AI holds promise in solving peptide design issues and predicting health effects of therapies
Delivery Breakthroughs: Recent technological advances improve delivery of biologic therapies
Unique Proposition: Bringing AI-driven synthetic biology to animal models of aging and neurodegeneration may unlock new insights and therapeutic opportunities
Directed Evolution
From Single Cells to Animals
Mother nature has already evolved systems for maintaining health and longevity
Directed evolution in the laboratory can build on the natural mechanisms of resilience to engineer interventions that further promote health and longevity
Our AIDEPT platform pairs Artificial Intelligence with Directed Evolution to engineer Peptide Therapeutics
Key Takeaways
Technology
The reduced cost and higher throughput of our proprietary transgenesis technology makes directed evolution in animal models feasible for the first time
Method
Engineer therapeutic peptides through directed evolution in animal models that better mirror the biology of human aging processes and neurodegeneration
Targets
Alzheimer’s disease, Parkinson’s disease, other age-related conditions, longevity enhancement, and metabolic disorders poorly modeled in single-cell systems
Team
Stephen Banse, PhD
Chief Executive Officer, President
Jesse Fittipaldi
Chief Strategy Officer
Cody Jarrett
Chief Technology Officer
Advisors
Zach Stevenson, PhD
Synthetic Biology, Genome Engineering
Allison Banse, PhD
Product Development
Nimet Maherali, PhD
Grant Writing, Scientific Communication
Robert Cosgriff
AI, Computer Vision